Common antidepressant may help adults with long COVID: study – National
The study was co‑led by researchers at McMaster University, alongside those in Brazil and the United States, conducting a clinical trial with 399 adults with fatigue persisting 90 or more days after confirmed SARS-CoV-2 infection.
The results found that fluvoxamine “showed a significant reduction in fatigue compared with placebo at day 60,” alongside “improv[ing] quality-of-life scores with high posterior probability.”
In a press release, Edward Mills, co‑principal investigator of the trial and professor in McMaster’s department of health research methods, evidence, and impact said that the research “is an important step forward for patients who have been desperate for evidence‑based options.”
“Fluvoxamine showed consistent and meaningful benefits, and because it’s already widely used and well understood, it has clear potential for clinical use.”
The 60-day clinical trial showed a 99 per cent probability that fluvoxamine outperformed the placebo for “reducing fatigue severity and improving quality of life in people with long COVID.”
Roger McIntyre, a psychiatry, pharmacology and toxicology professor at the University of Toronto, said that the findings from the study provide “a landscape sketch of what long COVID or post-COVID condition actually is.”
“One of the most common symptoms [of long COVID] is terrible fatigue,” he said. “Everyone experiences fatigue, that’s as human beings, but the fatigue that they’re experiencing is almost indescribable. They just can’t get off the couch fatigue, […] and it can be debilitating.”
McIntyre also said that the reason why fluvoxamine is being used in this area is because “it targets the immune inflammatory system.”
Get weekly health news
Receive the latest medical news and health information delivered to you every Sunday.
“Fluvoxamine is an anti-inflammatory drug along with being an antidepressant, and its anti-inflammatory properties are why it has been used in this regard,” he said.
“They have shown an improvement in fatigue, which seems to suggest that the fluvoxamine, perhaps through its effects on the inflammatory system, is reducing inflammation, and patients are reporting less fatigue, just like you would have less fatigue if you resolved your common cold,” he said.
However, Raymond Lam, a psychiatrist and department of psychiatry professor at the University of British Columbia, believes that more research is needed to decipher the difference between long COVID and depression.
“Depression is often a symptom of long COVID. People have this terrible fatigue and they get depressed,” he said. “What’s not clear is whether the fluvoxamine is just treating depression or depressive symptoms because fatigue is also a symptom of depression.”
According to Health Canada, fluvoxamine “belongs to a group of medicines called selective serotonin reuptake inhibitors (SSRIs).”
“Fluvoxamine is thought to work by increasing the levels of a chemical in the brain called serotonin (5-hydroxytryptamine).”
It is most commonly used to treat depression, bulimia and obsessive-compulsive disorder. An average daily dosage ranges from 20 mg to 60 mg, depending on a doctor’s prescription.
Story continues below advertisement
Maple Health Care, a virtual Canadian health care platform, currently lists several price ranges for both generic and name brand fluoxetine products:
- Generic 10 mg capsules: $155 to $160 for 100, $57 to $65 for 30
- Brand name 10 mg capsules: $335 to $360 for 100, $115 to $119 for 30
- Generic 20 mg capsules: $55 to $60 for 100, $25-30 for 30 caps
- Brand name 20 mg Capsule: $340 to $360 for 100, $115 to $119 for 30
There is also a liquid formula, which the 20 mg/5 mL strength generally costs $120-$135 for a brand name and $45 to $56 for a generic brand.
Maple Health Care also states that “insurance coverage typically ranges from 50 per cent to 100 per cent of the drug cost, making fluvoxamine accessible for many Canadians with coverage.”
In relation to treating long COVID, McIntrye “doesn’t anticipate” a future supply and demand issue.
“I don’t think that the world of medicine at this point is going to rapidly adopt this medicine because it has to be replicated. This is a first finding. And in medicine, we like to see replication before we make strong recommendations to start implementing it,” he said.
Lam also noted that “we shouldn’t disregard treatments that might be helpful, even if they’re antidepressants or psychiatric drugs, to save fluvoxamine.”
“We use a lot of medications off label, which means that it’s not officially approved for that purpose by Health Canada. So there’s no reason that people can’t use it.”
© 2026 Global News, a division of Corus Entertainment Inc.
Discover more from stock updates now
Subscribe to get the latest posts sent to your email.
